Infant Bacterial Therapeutics AB announced on October 8, 2018 that the members of its nomination committee, appointed for the Annual General Meeting 2019 in accordance with the AGM's decision, are Peter Rothschild, of Per-Erik Andersson, representative of the company's shareholder Annwall Rothschild Investments AB; Sebastian Jahreskog, representative of the company's second shareholder Banque Öhman SA; and Jannis Kitsakis, representative of the company's third shareholder, The Fourth Swedish National Pension Fund. Also, the chairman of Infant Bacterial Therapeutics' board of directors, Peter Rothschild, is a member of the nomination committee. All members of the nomination committee, apart from Rothschild, are independent in relation to the company and company management. Reportedly, the Annual General Meeting of 2018 decided that the chairman of the board of directors shall convene the three shareholders in the company, who each shall elect representative to be a member of the nomination committee, together with the chairman of the board.